How Credit Genie keeps codebase docs fresh with OpenWiki15m ago Google brings Gemini for desktop app to Windows27m ago Before AI Agents Take Action, Enterprises Need A New Data Rule Book45m ago Feature Engineering in Scikit-Learn: A KDnuggets Cheat Sheet46m ago Thomas Clozel, M.D., Co-Founder and CEO of Owkin – Interview Series47m ago Did OpenAI Steal A $1 Million Math Proof? Four Questions For Every CEO51m ago Build an end-to-end RFI questionnaire workflow using Amazon Quick Automate51m ago Anthropic skipped UK pre-release tests for Mythos 5.1, the FT reports53m ago Robotics Startup Skild AI Hits $100 Million in Revenue Run Rate2h ago Model-agnostic PII detection with LLMs58m ago Atlassian upgrades AI coding agents for always-on software development1h ago Universal Music is launching an AI music platform with ElevenLabs1h ago How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules1h ago Enterprise AI Is Moving Fast And Flying Blind1h ago

How Credit Genie keeps codebase docs fresh with OpenWiki15m ago Google brings Gemini for desktop app to Windows27m ago Before AI Agents Take Action, Enterprises Need A New Data Rule Book45m ago Feature Engineering in Scikit-Learn: A KDnuggets Cheat Sheet46m ago Thomas Clozel, M.D., Co-Founder and CEO of Owkin – Interview Series47m ago Did OpenAI Steal A $1 Million Math Proof? Four Questions For Every CEO51m ago Build an end-to-end RFI questionnaire workflow using Amazon Quick Automate51m ago Anthropic skipped UK pre-release tests for Mythos 5.1, the FT reports53m ago Robotics Startup Skild AI Hits $100 Million in Revenue Run Rate2h ago Model-agnostic PII detection with LLMs58m ago Atlassian upgrades AI coding agents for always-on software development1h ago Universal Music is launching an AI music platform with ElevenLabs1h ago How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules1h ago Enterprise AI Is Moving Fast And Flying Blind1h ago

Healthcare Machine Learning4 min reading time

Superluminal Medicines Raises $60M Series B to Advance Obesity Drug

Unite.AIPublished 7 days ago

Superluminal Medicines secured $60M in a Series B round led by BVF Partners to advance its selective MC4R agonist drug for rare genetic obesity into Phase 1 trials by end of 2026. The funding will also expand its GPCR-focused AI-driven drug discovery platform.

#biotechnology #bvf-partners #drug-discovery #mc4r #nvidia #ra-capital-management #superluminal-medicines

More in Healthcare

UK Is Urged to Overhaul Regulation of AI-Medical Devices

Covered by 2 sources18h ago

How a researcher uses Codex and ChatGPT to search for new antimicrobial molecules

Open AI News1h ago

Healthcare6 min read

NYU-DRP AI Model Predicts Five-Year Breast Cancer Risk From 3D Mammograms

Unite.AI6h ago